Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA

Stock Track

Aug 07, 2025

Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.

The biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.

Adding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1119661003"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119661003\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119661003?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119661003","market":"hk","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA","media":"Stock Track","content":"<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.</p>\n\n<p>The biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.</p>\n\n<p>Adding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Soars 5.86% After-Hours on Strong Q2 Results and FDA Acceptance of Filspari sNDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-07 06:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.</p>\n\n<p>The biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.</p>\n\n<p>Adding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1119661003","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119661003","pubTimestamp":1754518353,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"个股追踪|Travere Therapeutics盘后大涨5.86%Q2业绩强劲且FDA接受Filspari sNDA","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) surged 5.86% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter 2025 financial results and positive regulatory news.\nThe biopharmaceutical company reported a significant beat on both earnings and revenue for Q2 2025. Travere posted an adjusted earnings per share of $0.13, surpassing the analyst consensus estimate of -$0.28 by 146.43%. This marks a substantial improvement from the loss of $0.65 per share in the same period last year. Revenue for the quarter came in at $114.4 million, beating the analyst expectations of $101.38 million by 12.85% and representing a remarkable 119.26% increase year-over-year.\nAdding to the positive sentiment, Travere announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Filspari in the treatment of focal segmental glomerulosclerosis (FSGS). The PDUFA date has been set for January 13, 2026, potentially expanding the drug's market reach. Furthermore, the company reported a 165% surge in FILSPARI sales, contributing significantly to the strong quarterly performance. These developments have bolstered investor confidence in Travere's growth prospects and pipeline progress, likely driving the after-hours stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}